General discussion, page-2260

A few observations on psychedelics. Have done some extensive research in this sector looking at listed and unlisted players, institutes, universities and industry bodies as well as the evolution in this area of medicine.

1. There are no ASX competitors in the space.
2. Very little overseas re companies playing in the sector - and a lot of these are "aspirational".
3. Very very few are active in clinic trials and mostly claims are rhetoric.
4. Compass Holdings is perhaps the only real major player and they recently listed and now have a $1 B market cap.
5. Psychedelics, for those who know a bit about its history and evolution, has had a strong history of research and efficacy and it is now resurging. Treatments for PTSD, Depression and Palliative care have shown tremendous results far exceeding the Prozacs of the world and pure psychiatric approaches.
6. There are very few globally recognised experts in the field - we have one with Paul Liknaitzky. (worth researching Paul's profile)
7. The sector has a strong base in legitimacy - worth looking up Johns Hopkins and Usona Institute.

It should also be noted that the companies involved with clinical trials are under close scrutiny from partnering hospitals; a testament to the quality of medical talent IHL has been able to attract and the high standards it adopts.

IMO, IHL is at the forefront of this industry here in Australia and potentially in the top handful of companies at a global level. Very excited to see this unfold...has to be one of the most exciting companies developing unique CBD compound medicinal solutions and now a first mover of significance in psychedelics.